MeSH D014820 - vitiligo
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Incyte | Ruxolitinib | Opzelura | 2023-04-19 | $455.934 M | Q4/23-Q3/24 |
Clinical Trials
Historical Success Rate
Phase 1
75%9/12
Phase 2
21%6/28
Phase 3
57%4/7
Approved: 3Overall Success rate: 9%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use